Treatment of viral hepatitis in HIV coinfected patients adverse events and their management
|
|
- Howard Holt
- 5 years ago
- Views:
Transcription
1 Journal of Hepatology 44 (26) S114 S118 Treatment of viral hepatitis in HIV coinfected patients adverse events and their management Stefan Mauss* Center for HIV and Hepatogastroenterology, Grafenberger Allee 128a, 4237 Duesseldorf, Germany For the treatment of HBV/HIV-co-infection, study data on interferon-based therapy are very limited and insufficient to draw any specific conclusions. In contrast, data on HBV-polymerase inhibitors (lamivudine, adefovir, tenofovir) are available from controlled trials. Lamivudine is well tolerated and safe, however, development of HBVresistance is frequent. Adefovir has a nephrotoxic potential and may at least theoretically induce antiretroviral resistance in HBV/HIV-patients treated with adefovir. Tenofovir has gastrointestinal side effects, is associated with hypophospatemia, which has not induced serious osteopenia so far and may have a nephrotoxic potential. For HCV/HIV-co-infection pegylated interferon alpha plus ribavirin is standard of care. Flu-like symptoms, fatigue and depressive mood changes are frequent. In patients with a history of neurotic or minor depression initiation of treatment with antidepressants before the start of interferon-based therapy should be considered. Weight loss may be pronounced in individual cases. A marked decrease in absolute, but not relative CD4Gcells is the rule, but no relevant increase in opportunistic infection was observed, and anaemia (!1 g/dl) is reported in up to 3% of patients. Neutropenia (!1 cells/ml) is observed in up to 5% of the patients. Adverse events specific to the HCV/HIV-patient population as compared to HCV-mono-infected patients are the occurrence of hyperlactataemia/ lactic acidosis and hepatic decompensation. q 25 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. Keywords: Hepatitis; HIV; Therapy; Adverse events; Coinfection 1. HBV/HIV-co-infection In HBV/HIV-co-infection, no studies of an adequate size are available for interferon-based therapy. The largest trials have a size of less than 3 patients [1 3]. In particular, virtually no valid data on the use of pegylated interferon in the treatment of HBV/HIV-co-infection exist. For this, management recommendations can only be extrapolated from the experience in HBV-mono-infected or interferon monotherapy used in HCV/HIV-co-infected patients. In contrast, there are sufficient data on the use of lamivudine in HBV/HIV-co-infected patients. The prospective controlled data are from antiretroviral treatment including HBV/HIV-patients as a subpopulation [4,5]. In general, lamivudine was well tolerated with no major * Tel.: C ; fax: C address: maussst@compuserve.com (S. Mauss). adverse events associated with the drug different from placebo. There were no specific tolerance problems reported in HBV/HIV-co-infected patients for lamivudine compared to HIV-mono-infected or HBV-mono-infected patients. A specific consideration has to be given to the possibility of an exacerbation of hepatitis B in patients in whom lamivudine was discontinued due to antiretroviral failure [6,7] or in whom lamivudine resistance of the hepatitis B virus occurred [8]. Data for adefovir for HBV/HIV-co-infected patients are only available for a small number of patients in a prospective, uncontrolled study showing excellent tolerance [9,1]. No clinical renal complications were observed in this limited number of patients at the standard daily dose of 1 mg [11]. In HBV-mono-infected patients, adefovir was approved at a daily dose of 1 mg/d, because daily doses of 2 mg and higher were associated with renotubular failure resembling Fanconi s syndrome and increases in serum /$3. q 25 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. doi:1.116/j.jhep
2 S. Mauss / Journal of Hepatology 44 (26) S114 S118 S115 creatinine. In general, the concomitant use of adefovir with nephrotoxic agents or in patients with pre-existing renal impairment should be avoided or closely monitored. A potential adverse event of adefovir when used in a dose considered not effective for antiretroviral therapy, could be the induction of antiretroviral cross resistance. The existing database does not prove this theoretical risk but is too small to exclude it [12]. Most of the reported studies with tenofovir are uncontrolled and do not report a specific adverse event profile compared to HIV-mono-infected patients [13 16]. In general, tenofovir is associated with adverse events such as nausea, abdominal pain and diarrhoea [17]. Anecdotal data associating tenofovir with renal failure are reported [18 21], but in controlled studies and observational cohorts no marked increases in serum creatinine were observed [17,22]. However, with more sensitive methods an increased frequency of proteinuria and reduced renal clearance was observed in cross sectional studies [23]. Until the availability of more detailed renal safety data, tenofovir should only be used with caution in combination with nephrotoxic agents or in patients with pre-existing renal impairment. The clinical relevance of phosphaturia, which raised concerns about an increased incidence of premature osteoporosis, has still to be validated for prolonged exposure to tenofovir. During an observational period of 3 years no significant reduction of bone density in patients treated with tenofovir was found [17]. 2. HCV/HIV-co-infection Standard therapy for the treatment of chronic hepatitis C in HIV-co-infected individuals is pegylated interferon plus ribavirin. This has been shown in several prospective, controlled trials [24 27]. These trials are the largest trials performed in HCV/HIV-co-infection and will be the basis for the following assessment of safety and tolerance issues. The most common clinical adverse events in HCV/HIVco-infected patients under treatment with pegylated interferon plus ribavirin are listed in Table 1. Flu-like symptoms, Table 1 Most frequent adverse events associated with interferon-based therapy in APRICOT IFN alpha- 2aCRBV (nz285) (%) PEG-IFN alpha-2a (4 kda) CPlacebo (nz286) (%) Fatigue Pyrexia Headache Myalgia Nausea Insomnia Asthenia Depression Possibly or probably related. PEG-IFN alpha-2a (4 kda) CRBV (nz288) (%) asthenia, gastrointestinal disorders and depressive mood changes are most frequently observed. Serious neuropsychiatric disorders and attempted or completed suicides are reported in less than.5% of the study population [24 29]. The treatment of these adverse events is based on the decision of the treating physician and no clinical trials on the use of optimal medication or dose are available. The common approach to flu-like symptoms is the use of paracetamol or other NSAIDs, in particular before the injection of interferon. Low platelets are a relative contraindication for the use of acetylsalicylic acid, diclofenac or ibuprofen, because of the inhibition of platelet aggregation. Nausea can be reduced by using metoclopramide. Antidepressants, frequently used in the study population of recent trials, are selective serotonin re-uptake inhibitors such as citaprolamin, paroxetin or tricyclic antidepressants such as doxepine [26,3]. However in general, cooperation with an experienced psychiatrist to establish a standardized treatment procedure is recommended. In patients with preexisting depressive mood disorders or other profound neurotic disorders, initiation of specific psychiatric medication is recommended to reduce the destabilizing effect of interferon-based therapy. In patients with a history of hospitalisation due to major depression or psychosis, interferon-based therapy is generally contraindicated. In rare exceptions treatment can be initiated in a closely controlled setting. Benzodiazepines should be avoided in patients with a history of intravenous drug use, because of their potential to induce addiction. Adverse events specific for HCV/HIV-co-infected patients are partially explained by the interaction of antiretroviral agents and interferon-based therapy. Ribavirin competes for phosphorylation with thymidine- or cytosine analogues such as zidovudine or stavudine [31,32]. However, in controlled trials, no effect of ribavirin on the efficacy of antiretroviral combination therapy was observed [27]. Interferon has a moderate antiretroviral effect, which may compensate for any inhibitory effect of ribavirin on the efficacy of the antiretroviral regimen [27]. In contrast, the phosphorylation of didanosine is increased by ribavirin, which may explain some of its adverse event profile observed in HCV/HIV-co-infected patients [33]. Didanosine was shown to be associated with a markedly increased risk of lactic acidosis and hyperlactaemia in a multivariate analysis, particularly when used in combination with stavudine [24]. In addition, didanosine was reported to be associated with pancreatitis in an uncontrolled trial [34]. In a multivariate analysis, didanosine was associated with hepatic decompensation in patients with liver cirrhosis [35]. In conclusion, didanosine should be discontinued in patients starting interferon-based therapy whenever possible. The use of zidovudine is associated with an increased frequency of anaemia, but not severe neutropenia [36]. The use of zidovudine should therefore be avoided in patients with alternative antiretroviral options.
3 S116 S. Mauss / Journal of Hepatology 44 (26) S114 S118 Fitted Probability no ddi; low bili; Hb = 14.9 g/dl no ddi; high bili; Hb = 14.9 g/dl ddi; low bili; Hb = 14.9 g/dl ddi; high bili; Hb = 14.9 g/dl ddi; high bili; Hb = 1.3 g/dl Platelet Count (x 1 9 /L) Fig. 1. Risk factors associated with hepatic decompensation in the multivariate modelling with risk factors identified in the univariate analysis from Ref. [35]. Reproduced with permission from AIDS 24;18:F21 F25. In the two largest controlled trials in HCV/HIV-coinfection an unexpected number of hepatic decompensations was noted [24,35]. Whereas there is no specific information for the hepatic decompensation cases available from RIBAVIC, in APRICOT all patients with hepatic decompensation had liver cirrhosis. The incidence of hepatic decompensation in cirrhotic patients was about 1%. In a multivariate analysis, the baseline risk factors identified included markers of advanced cirrhosis and the use of didanosine (Fig. 1). In consequence, patients with early stages of cirrhosis should be treated with caution under frequent clinical monitoring, whereas didanosine should be regarded as a risk factor and avoided in these patients. The average weight loss in interferon-based controlled studies is around 5 kg. There is no consistent reporting on the weight loss in the studies treating HIV/HCV-co-infected patients, but in the few studies where these data are available, the weight loss does not seem to be markedly different from HCV-mono-infected patients [29]. However, weight loss may aggravate lipoatrophy associated with antiretroviral treatment. Interferon-based therapy is accompanied by a marked drop in absolute, but not relative, CD4-positive cell count (Fig. 2). This change in the cellular immune system did not result in an increased number of opportunistic infections [24,26,27]. Anaemia (!1 g/dl) is reported in up to 3% of the patients increasing with the concomitant use of zidovudine and a lower baseline haemoglobin [25 28,36]. Although controlled studies are missing it is highly likely that higher doses of ribavirin, than the 8 mg daily dose used in most HCV/HIV-co-infection studies, will result in an increased incidence of anaemia as shown for HCV-mono-infected patients [37]. Erythropoetin can be successfully used to correct the ribavirin-induced anaemia at least partially and to avoid dose reduction or red blood cell transfusions. However larger prospective, controlled trials as for HCVmono-infected patients are missing [38,39]. At present CD4 + cells/µl % CD4 + cells IFN alfa-2a 3 MIU + RBV 8 mg (n = 174) PEG-IFN alfa-2a (4 kda) 18 ug + Placebo (n = 196) PEG-IFN alfa-2a (4 kda) 18 ug + RBV 8 mg (n = 217) Time (Weeks) IFN alfa-2a 3 MIU + RBV 8 mg (n = 174) PEG-IFN alfa-2a (4 kda) 18 ug + Placebo (n = 196) PEG-IFN alfa-2a (4 kda) 18 ug + RBV 8 mg (n = 217) Time (Weeks) * Patients receiving 48 weeks of treatment Fig. 2. Median change in absolute Cd4Gcell count (top) and relative CD4Gcell count (bottom)*. [This figure appears in colour on the web.] erythropoietin is not approved for correction of ribavirininduced anaemia. Neutropenia (!1 neutrophils/ml) is another frequent laboratory adverse event and reported in up to 5% of the study participants [25,26]. Although in some studies granulocyte-colony stimulating factors were used for correction of neutropenia, the clinical significance of the neutropenia remains unproven. In general, the combined incidence of bacterial or opportunistic infections is low (!5%) in the presented studies. In addition to a relevant immunosuppression in a proportion of study participants the majority of patients have a history of intravenous drug use, which may result in a higher risk of sepsis, pneumonia and abscesses in some patients. Systematic adherence data are not available to date, however treatment discontinuations due to adverse events or patient request can be used as a surrogate. In the earlier uncontrolled HCV/HIV-co-infection studies, the discontinuation rate was around 3% e.g. Refs. [29,4,41], but in the more recent studies with pegylated interferons, premature treatment discontinuation ranged from 12 to 17% [24 27] and is comparable to the proportion discontinuing prematurely in the pivotal trials in HCVmono-infected patients [42,43]. In summary, the toxicity of interferon-based therapy in HIV/HCV-co-infected patients is considerable and requires active management and profound knowledge about antiretroviral treatment, which may contribute substantially to complications during hepatitis therapy. To keep the
4 S. Mauss / Journal of Hepatology 44 (26) S114 S118 S117 incidence of adverse events as low as possible, the optimal dosing and treatment duration of pegylated interferon and ribavirin in HCV/HIV-co-infected patients according to HCV-genotype, cellular immune status or early viral response should be addressed in the near future. As a more distant goal, new anti HCV-agents with a better tolerability profile and possibly a better efficacy will be a major step to improve the access to HCV-treatment for HCV/HIV-co-infected patients. References [1] Di Martino V, Thevenot T, Colin JF, Boyer N, Martinot M, Degos F, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 22;123: [2] Wong DK, Yim C, Naylor CD, Chen E, Sherman M, Vas S, et al. Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology 1995; 18: [3] Zylberberg H, Jiang J, Pialoux G, Driss F, Carnot F, Dubois F, et al. Alpha-interferon for chronic active hepatitis B in human immunodeficiency virus-infected patients. Gastroenterol Clin Biol 1996;2: [4] Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, et al. The effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996;125: [5] Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-co-infected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 1999;18: [6] Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2;32: [7] Petry W, Adams O, Haussinger D. Fatal hepatitis B reinfection after orthotopic liver transplantation in an HBsAg negative patient following withdrawal of lamivudine. J Hepatol 2;33: [8] Bonacini M, Kurz A, Locarnini S, Ayres A, Gibbs C. Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient co-infected with HIV. Gastroenterology 22;122: [9] Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus. Lancet 21; 358: [1] Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, et al. Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV infected patients. J Hepatol 22;36:138. [11] Hannon H, Bagnis CI, Benhamou Y, Beaufils H, Sullivan M, Brosgart C, et al. The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV. Nephrol Dial Transplant 24;19: [12] Delaugerre C, Marcelin AG, Thibault V, Peytavin G, Bombled T, Bochet MV, et al. Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)- HIV-co-infected patients treated for HBV chronic infection once daily with 1 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob Agents Chemother 22;46: [13] Benhamou Y, Bochet M, Tubiana R, Thibault V, Suffisseau L, Sullivan M, et al. Tenofovir disoproxil fumarate suppresses lamivudine resistant HBV replication in patients co-infected with HIV/HBV. N Engl J Med 23;348: [14] Nelson M, Portsmouth S, Stebbing J, Atkins M, Barr A, Matthews G, et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 23;17:F7 F1. [15] Ristig MB, Crippin J, Aberg JA, Powderly WG, Lisker-Melman M, Kessels L, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 22;186: [16] Van Bömmel F, Wunsche T, Schurmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 22;36: [17] Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. For the 93 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviralnaive patients: a 3-year randomized trial. J Am Med Assoc 24;292: [18] Breton G, Alexandre M, Duval X, Prie D, Peytavin G, Leport C, et al. Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1. Scand J Infect Dis 24;36: [19] Hansen AB, Mathiesen S, Gerstoft J. Severe metabolic acidosis and renal failure in an HIV-1 patient receiving tenofovir. Scand J Infect Dis 24;36: [2] Rifkin BS, Perazella MA. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med 24;117: [21] Saumoy M, Vidal F, Peraire J, Sauleda S, Vea AM, Vilades C, et al. Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity? AIDS 24;18: [22] Jones R, Stebbing J, Nelson M, Moyle G, Bower M, Mandalia S, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: cohort and case control study. J Acquir Immune Defic Syndr 24;37: [23] Mauss S, Berger F, Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 25;19: [24] Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. For the ANRS HCO2 RIBAVIC Study Team. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. J Am Med Assoc 24;292: [25] Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. For the AIDS Clinical Trials Group A571 Study Team. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-co-infected persons. N Engl J Med 24;351: [26] Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, Sanchez- Tapias JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV coinfected patients. AIDS 24;18:F27 F34. [27] Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez- Garcia J, Lazzarin A, et al. For the APRICOT Study Group. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 24;351: [28] Moreno L, Quereda C, Moreno A, Perez-Elias MJ, Antela A, Casado JL, et al. Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS 24;18: [29] Pérez-Olmeda M, Nunez M, Romero M, Gonzalez J, Castro A, Arribas JR, et al. Pegylated interferon-a 2bC ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 23;17: [3] Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 22;16: [31] Hoggard PG, Kewn S, Barry MG, Khoo SH, Back DJ. Effects of drugs on 2,3 -dideoxy-2,3 -didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother 1997;41:
5 S118 S. Mauss / Journal of Hepatology 44 (26) S114 S118 [32] Vogt MW, Hartshorn KL, Furman PA, Chou TC, Fyfe JA, Coleman LA, et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987;235: [33] Japour AJ, Lertora JJ, Meehan PM, Erice A, Connor JD, Griffith BP, et al. A phase-i study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13: [34] Soriano V, Rodriguez-Rosado R, Perez-Olmeda M, Romero M, Garcia-Samaniego J. Interferon plus ribavirin for chronic hepatitis C in HIV-infected patients. AIDS 2;14: [35] Mauss S, Valenti W, DePamphilis J, Duff F, Cupelli L, Passe S, et al. Risk factors for hepatic decompensation in patients with HIV/HCV co-infection and liver cirrhosis during interferon-based therapy. AIDS 24;18:F21 F25. [36] Brau N. Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C. J Viral Hepat 24;11: [37] Hadziyannis SJ, Sette Jr H, Morgan TR, Balan V, Diago M, Marcellin P, et al. For the PEGASYS International Study Group: peginterferon-alpha2a and ribavirin in combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 24;14: [38] Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, et al. For the PROACTIVE Study Group. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 24;4: [39] Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, et al. For the Proactive Study Group. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 24; 126: [4] Landau A, Batisse D, Piketty C, Duong Van Huyen JP, Bloch F, Belec L, et al. Long-term efficacy of combination therapy with interferon-a 2b and ribavirin for severe chronic hepatitis C in HIVinfected patients. AIDS 21;15: [41] Rockstroh JK, Mudar M, Lichterfeld M, Nischalke HD, Klausen G, Golz J, et al. For the German Clinical AIDS Working Group (KAAD). Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients. AIDS 22;16: [42] Fried M, Shiffman M, Reddy R, Smith C, Marinos G, Goncales Jr FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 22;347: [43] Manns M, McHutchison J, Gordon S, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 21;358:
The medical management of hepatitis C
CLINICAL EXPERIENCE WITH PEGYLATED INTERFERON α-2a PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C VIRUS INFECTION IN PATIENTS INFECTED WITH HIV: THE APRICOT STUDY Douglas T. Dieterich, MD* ABSTRACT Currently,
More informationOver the past decade, the introduction of
MANAGEMENT OF CHRONIC HEPATITIS C IN HIV-INFECTED PATIENTS: CLINICAL EXPERIENCE WITH PEGYLATED INTERFERON α PLUS RIBAVIRIN Raymond T. Chung, MD* ABSTRACT Coinfection with hepatitis C virus (HCV) is common
More informationTreatment algorithm for the management of hepatitis C in HIV-coinfected persons
Journal of Hepatology 44 (2006) S49 S55 www.elsevier.com/locate/jhep Treatment algorithm for the management of hepatitis C in HIV-coinfected persons Mark S. Sulkowski* Johns Hopkins Medical Institutions,
More informationAnemia in the Treatment of Hepatitis C Virus Infection
SUPPLEMENT ARTICLE Anemia in the Treatment of Hepatitis C Virus Infection Mark S. Sulkowski Center for Viral Hepatitis, Johns Hopkins University, Baltimore, Maryland Hepatitis C virus (HCV) infection is
More informationIntravenous drug use is currently the main transmission
A Prospective Controlled Study of Interferon-Based Therapy of Chronic Hepatitis C in Patients on Methadone Maintenance Stefan Mauss, 1 Florian Berger, 1 Joerg Goelz, 2 Bernhard Jacob, 3 and Günther Schmutz
More informationTreatment of HCV and HIV coinfection
Annals of Hepatology 2006; 5(Suppl. 1): S42-S48 Annals of Hepatology Treatment of HCV and HIV coinfection J. Alberto Juárez Navarro 1 Chronic infection with hepatitis C virus (HCV) affects 170 million
More informationCurrent therapy for hepatitis C: pegylated interferon and ribavirin
Clin Liver Dis 7 (2003) 149 161 Current therapy for hepatitis C: pegylated interferon and ribavirin John G. McHutchison, MD a, Michael W. Fried, MD b, * a Duke Clinical Research Institute, Duke University
More informationTreatment of Chronic Hepatitis B in HIV-Infected Persons: Thinking Outside the Black Box
VIEWPOINTS HIV/AIDS Treatment of Chronic Hepatitis B in HIV-Infected Persons: Thinking Outside the Black Box Chloe L. Thio, Mark S. Sulkowski, and David L. Thomas Department of Medicine, Johns Hopkins
More informationHIV and Hepatitis C Virus Coinfection: Bad Bedfellows
Perspective HIV and Hepatitis C Virus Coinfection: Bad Bedfellows Hepatitis C virus (HCV) infection is common in HIV-infected individuals and is responsible for increasing morbidity in these patients.
More informationhepatitis B virus B 15% 25 HBsAg B HBV HBsAg 15% 20% HBV HBV 90% 16 HIV HBV
hepatitis virus HV 20 15% 25 20 30 HV HsAg 3 5 100 HV 15% 20% HV HsAg HV HV HV 90% 16 5% HV 10 59 http://www.aids-care.org.tw HV CD8 73% 98% HV 90% HV HsAg 6 10% HsAg 0.5% 1% HV HV HV HV HCV TNF- TNF-
More informationIntron A Hepatitis B. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.01 Subject: Intron A Hepatitis B Page: 1 of 7 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationHIV and Hepatitis C: Advances in Treatment
NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV and Hepatitis C: Advances in Treatment John Scott, MD, MSc Asst Professor University of Washington Presentation prepared & presented by: John Scott, MD,
More informationORIGINAL RESEARCH. Introduction
DOI: 10.1111/ j.1468-1293.2007.00535.x HIV Medicine (2008), 9, 82 88 ORIGINAL RESEARCH r 2008 British HIV Association European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationLearning Objectives. Disclosures (Activity w/i 12 months) WHY DISCUSS HCV/HIV COINFECTION? HCV/HIV Effect on Health Utilization in A5001
Learning Objectives HCV/HIV COINFECTION Soup to Nuts Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine At the
More informationHepatitis C Treatment
Hepatitis C Treatment Standard of care & Managing advrse events Mohssen Nassiri Toosi, MD A s s o c i a t e P ro f e s s o r Of Internal M e d i c i n e Te h r a n U n i v e r s i t y O f M e d i c a l
More informationTreatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D.
Session IV Treatment Options in HCV Relapsers and Nonresponders Raymond T. Chung, M.D. Director of Hepatology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston,
More informationDual Therapy for Chronic Hepatitis B Virus
Dual Therapy for Chronic Hepatitis B Virus Hussien Elsiesy, MD, and Douglas Dieterich, MD Corresponding author Douglas Dieterich, MD Division of Liver Diseases, Mount Sinai School of Medicine, One Gustave
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationTreatment of HCV in HIV/HCV Coinfection: What Are the New Questions?
Treatment of HCV in HIV/HCV Coinfection: What Are the New Questions? Reprinted from The prn Notebook june 2005 Dr. James F. Braun, Editor-in-Chief Tim Horn, Executive Editor. Published in New York City
More informationPegasys Pegintron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.47 Subsection: Anti-infective nts Original Policy Date: January 1, 2019 Subject: Pegasys Pegintron
More informationReviews/Evaluations. Chronic Hepatitis C. Introduction and Epidemiology. Natural Course of HCV. Recommendations for Treatment
Reviews/Evaluations Chronic Hepatitis C Introduction and Epidemiology Hepatitis C virus (HCV) is one of the most common blood-borne infections and cause of chronic liver disease in the United States (1).
More informationPegasys Hepatitis B. Pegasys (peginterferon alfa-2a) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.02 Subject: Pegasys Hepatitis B Page: 1 of 5 Last Review Date: September 18, 2015 Pegasys Hepatitis
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationThe role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International
More informationPegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience
Pegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience E L Seow, PH Robert Ding Island Hospital, Penang, Malaysia. Introduction Hepatitis
More informationTreatment Outcome in Chronic Hepatitis C Infection: A Four Years Survey Among Iranian Patients
Global Journal of Health Science; Vol. 7, No. 3; 2015 ISSN 1916-9736 E-ISSN 1916-9744 Published by Canadian Center of Science and Education Treatment Outcome in Chronic Hepatitis C Infection: A Four Years
More informationةي : لآا ةرقبلا ةروس
سورة البقرة: اآلية HCV RELAPSERS AND NONRESPONDERS: How to deal with them? BY Prof. Mohamed Sharaf-Eldin Prof. of Hepatology and Gastroenterology Tanta University Achieving SVR The ability to achieve a
More informationIntron A HEPATITIS B. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.01 Subject: Intron A Hepatitis B Page: 1 of 8 Last Review Date: September 18, 2015 Intron A HEPATITIS
More informationSECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM
SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN Background Hepatitis
More informationManagement of HBV in KidneyTransplanted Patients Dr.E.Nemati
Management of HBV in KidneyTransplanted Patients Dr.E.Nemati Hepatitis B virus (HBV) infection Hepatitis B virus (HBV) infection confers a significantly negative impact on the clinical outcomes of kidney
More informationHepatitis C & HIV Coinfection and Brief Advances on Hepatitis B & HIV: The Evidence and New Proposals
Hepatitis C & HIV Coinfection and Brief Advances on Hepatitis B & HIV: The Evidence and New Proposals Douglas G. Fish, MD Albany Medical College April 3, 2009 Cali Colombia Objectives HCV Epidemiology
More informationPrediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015
THAI J 16 GASTROENTEROL Treatment with Nucleos(t)ide Original Analogues Article Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term Treatment with Nucleos(t)ide Analogues Sombutsook
More informationDescriptive study of incidence of side effects of Pegylated interferon
alpha therapy and their relation to age, gender, duration of treatment and type of hepatitis in 0 Iraqi patients. Original Article Descriptive study of incidence of side effects of Pegylated interferon
More informationSCIENTIFIC DISCUSSION
London, 26 April 2007 Product name: PegIntron Procedure No: EMEA/H/C/000280/II/0068 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18
More informationTreatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases
Journal of Viral Hepatitis, 2005, 12, 207 211 doi:10.1111/j.1365-2893.2005.00580.x Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases M. Vogel,
More informationHIV coinfection and HCC
HIV coinfection and HCC 3 rd APASL STC on HCC 21 st -23 rd Nov 2013 Cebu, Phillippines George KK Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond) Consultant, Humanity and Health GI
More informationScottish Medicines Consortium
Scottish Medicines Consortium tenofovir disoproxil (as fumarate), 245 mg film-coated tablet (Viread ) No. (479/08) Gilead Sciences 06 June 2008 The Scottish Medicines Consortium has completed its assessment
More informationOur better understanding of the natural
TREATMENT OF CHRONIC HEPATITIS B: MASTERING THE BASICS ON A COMPLEX TOPIC Ke-Qin Hu, MD* ABSTRACT The availability of newer antiviral agents, as well as comprehensive treatment recommendations, has equipped
More informationManagement of Decompensated Chronic Hepatitis B
Management of Decompensated Chronic Hepatitis B Dr James YY Fung, FRACP, MD Department of Medicine The University of Hong Kong Liver Transplant Center Queen Mary Hospital State Key Laboratory for Liver
More informationTRANSPARENCY COMMITTEE OPINION. 8 July 2009
The legally binding text is the original French version TRAPARENCY COMMITTEE OPINION 8 July 2009 VIREAD 245 mg film-coated tablets Bottle 30 tablets (CIP: 358 500-1) Applicant: GILEAD SCIENCES Tenofovir
More informationThe treatment of choice for chronic hepatitis C is
Early Identification of HCV Genotype 1 Patients Responding to 24 Weeks Peginterferon -2a (40 kd)/ribavirin Therapy Donald M. Jensen, 1 Timothy R. Morgan, 2 Patrick Marcellin, 3 Paul J. Pockros, 4 K. Rajender
More informationPredictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV HCV-coinfected patients
Antiviral Therapy 12:1225 1235 Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV HCV-coinfected patients José A Mira 1, Luis F López-Cortés
More informationVemlidy. (tenofovir alafenamide) New Product Slideshow
Vemlidy (tenofovir alafenamide) New Product Slideshow Introduction Brand name: Vemlidy Generic name: Tenofovir alafenamide Pharmacological class: Nucleoside analogue (reverse transcriptase inhibitor) Strength
More informationHCV / HIV Co i n f ec t i o n
c h a p t e r HCV / HIV Co i n f ec t i o n Tina M. St. John, MD and Misha Cohen, OMD, LAc 20 S E C T I O N 2 Western (Allopathic ) Treatment Options Introduction The management and treatment of coinfection
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationHBV Therapy in Special Populations: Liver Cirrhosis
HBV Therapy in Special Populations: Liver Cirrhosis Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationTherapy of Hepatitis C. Adrian M. Di Bisceglie
Session V Therapy of Hepatitis C Adrian M. Di Bisceglie Saint Louis University Liver Center, St. Louis, Mo. Tremendous progress has been made in developing effective therapies for hepatitis C. The process
More informationTherapy Analysis and Evidenced-Based Treatment Guidelines (Including Review of Antiviral Medications)
Therapy Analysis and Evidenced-Based Treatment Guidelines (Including Review of Antiviral Medications) Jason Smith, PharmD ABSTRACT OBJECTIVE: To summarize current treatment options and guidelines for treatment
More informationPharmacological management of viruses in obese patients
Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician
More informationShould Elderly CHC Patients (>70 years old) be Treated?
Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,
More informationTreatment Op+ons for Chronic Hepa++s B. Judith Feinberg, MD Project ECHO Jan. 19, 2017
Treatment Op+ons for Chronic Hepa++s B Judith Feinberg, MD Project ECHO Jan. 19, 2017 Treatment of Chronic Hepatitis B can be prevented by vaccinacon (part of infant series since 1992-3) goal of drug therapy
More informationCase report Reversibility of cirrhosis in HIV/HBV coinfection
Case report Reversibility of cirrhosis in HIV/HBV coinfection Vincent O Mallet 1,2,3 *, Valérie Dhalluin-Venier 1,2, Virginie Verkarre 1,4, Jean-Michel Correas 1,5, Marie-Laure Chaix 1,6, Jean-Paul Viard
More informationImportant Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. For Healthcare Providers
Important Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication For Healthcare Providers About TRUVADA for a PrEP Indication INDICATION AND PRESCRIBING CONSIDERATIONS TRUVADA,
More informationSovaldi (sofosbuvir) with Pegasys (peginterferon alfa-2a) and Ribavirin (Copegus, Moderiba, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.25 Subject: Sovaldi Pegasys Ribavirin Page: 1 of 6 Last Review Date: December 8, 2017 Sovaldi Pegasys
More informationImportant Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP)
Important Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) For Healthcare Providers About Emtricitabine/Tenofovir Disoproxil
More informationTenofovir disoproxil STADA 245 mg film-coated tablets , Version 1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Tenofovir disoproxil STADA 245 mg film-coated tablets 9.3.2016, Version 1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology HIV-1 infection
More informationTreatment of HCV in Persons with HIV Coinfection
Hepatitis C Online PDF created October 2, 2018, 12:45 pm Treatment of HCV in Persons with HIV Coinfection This is a PDF version of the following document: Section 6: Treatment of Key Populations and Unique
More informationClinical Infectious Diseases Advance Access published September 3, 2014
Clinical Infectious Diseases Advance Access published September 3, 2014 1 Acute hepatitis C virus infection in HIV+ MSM: Should we change our screening practice? Reiberger T. Division of Gastroenterology
More informationStrategies for Managing Hepatitis C Virus Infection in HIV-Infected Patients
Perspective Strategies for Managing Hepatitis C Virus Infection in HIV-Infected Patients Challenges in the Management of HIV/HCV Coinfection Hepatitis C virus (HCV) infection is a common comorbidity in
More informationProfessor Vincent Soriano
Five Nations Conference on HIV and Hepatitis in partnership with Professor Vincent Soriano Hospital Carlos III, Madrid, Spain Professor Vincent Soriano in partnership with Hospital Carlos III, Madrid,
More informationPEARL-I. Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4. Treatment Naïve and Treatment Experienced
Phase 2b Treatment Naïve and Treatment Experienced Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I Hézode C, et al. Lancet. 2015 March 30. [Epub ahead of print] PEARL-I: Study Design
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationOptimal Dosing Frequency of Pegylated Interferon Alfa-2b Monotherapy for Chronic Hepatitis C Virus Infection
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:610 615 Optimal Dosing Frequency of Pegylated Interferon Alfa-2b Monotherapy for Chronic Hepatitis C Virus Infection YOAV LURIE,* REGINE ROUZIER PANIS, GEORGE
More informationGilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting 2018
Gilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting 2018 October 11, 2018 3:24 PM ET -- More Than 50 Abstracts Across NASH, PSC, HBV and HCV Reflect
More informationHIV, HCV, interferon, lymphopenia, neutropenia, ribavirin, thrombopenia
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.01023.x Modifications of haematological series in patients co-infected with human immunodeficiency virus and hepatitis C virus during treatment with and ribavirin:
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationEmtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) Training Guide for Healthcare Providers
Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) Training Guide for Healthcare Providers About emtricitabine/tenofovir disoproxil fumarate for HIV-1 PrEP
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationReview Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3
Review Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3 Thomas Berg 1 * and Giampiero Carosi 2 Antiviral Therapy 13 Suppl 1:17 22 1 Charite Universitatsmedizin Berlin, Berlin, Germany
More informationViral hepatitis and HIV coinfection q
Journal of Hepatology 48 (2008) 353 367 Review Viral hepatitis and HIV coinfection q www.elsevier.com/locate/jhep Mark S. Sulkowski * Johns Hopkins University School of Medicine, 600 rth Wolfe Street,
More informationOlysio Pegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.28 Subject: Olysio Pegasys Ribavirin Page: 1 of 8 Last Review Date: December 18, 2017 Olysio Pegasys
More informationDr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust
Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationHigher Risk of Hyperglycemia in HIV-Infected Patients Treated with Didanosine Plus Tenofovir
6131_06_p333-337 4/5/06 10:28 AM Page 333 AIDS RESEARCH AND HUMAN RETROVIRUSES Volume 22, Number 4, 2006, pp. 333 337 Mary Ann Liebert, Inc. Higher Risk of Hyperglycemia in HIV-Infected Patients Treated
More informationAcute Hepatitis B Virus Infection with Recovery
Hepatitis B: Clear as Mud Melissa Osborn, MD, MSCR Assistant Professor Emory University School of Medicine Atlanta, GA 1 Objectives 1. Distinguish the various stages in the natural history of chronic hepatitis
More informationCase #1. Case #1. Case #1: Audience vote VS. The Great Debate: When to Treat HCV in our HIV coinfected patients
Case #1 The Great Debate: When to Treat HCV in our HIV coinfected patients Medical Management of AIDS December, 2012 Moderated by George Beatty,MD 35 year old African American man, CD4 + 450, HIV RNA
More informationClinical Policy: Hepatitis B Drugs Reference Number: AZ.CP.PHAR.03 Effective Date: Last Review Date: Line of Business: Arizona Medicaid
Clinical Policy: Reference Number: AZ.CP.PHAR.03 Effective Date: 11.16.16 Last Review Date: 08.18 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationNUCs for Chronic Hepatitis B. Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona.
NUCs for Chronic Hepatitis B Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona. Spain Disclosures Advisory board of, and/or, received speaker fee from
More informationEmerging Drug List ADEFOVIR DIPIVOXIL FOR HEPATITIS B VIRUS INFECTION NO. 48 SEPTEMBER Generic (Trade Name): Adefovir dipivoxil (Hepsera TM )
Generic (Trade Name): Manufacturer: Adefovir dipivoxil (Hepsera TM ) Gilead Sciences, Inc. NO. 48 SEPTEMBER 2003 Indication: Current Regulatory Status: For the treatment of adults showing evidence of active
More informationEmtricitabine / Tenofovir disoproxil Stada 200 mg/245 mg film-coated tablets , Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Emtricitabine / Tenofovir disoproxil Stada 200 mg/245 mg film-coated tablets 30.5.2016, Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a public summary Emtricitabine / Tenofovir
More informationHepatitis B and C. And the rest of the alphabet
Hepatitis B and C And the rest of the alphabet Adapté des exposés de la Chaire Franqui 2003 "Antiviral drugs and Discoveries in Medicine" Prof. E. De Clercq, KU-Leuven http://www.md.ucl.ac.be/chaire-francqui/
More informationPoor response to hepatitis C treatment in elderly patients
392 ORIGINAL ARTICLE May-June, Vol. 12 No.3, 2013: 392-398 Poor response to hepatitis C treatment in elderly patients Ivonete Silva, Roberto Carvalho Filho, Ana Cristina Feldner, Iandra Zaros, Antonio
More informationTemporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV
Case report Antiviral Therapy 11:647 652 Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV Karsten Wursthorn 1, Peter Buggisch 1,
More informationChronic Hepatitis B: management update.
Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)
More informationEU-Risk Management Plan for Emtricitabine/Tenofovir (NL/H/3635/001/DC and NL/H/3636/001/DC) V1.3
VI.2 Elements for a public summary 200 mg/245 mg film-coated tablets VI.2.1 Overview of disease epidemiology HIV-1 infection In this decade, the global prevalence of HIV-1 infection stabilized
More informationHBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But
HBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But Hospital Universitario Valle Hebron and Ciberehd del Insttuto Carlos III. Barcelona. Spain Disclosures Advisory board of,
More informationHepatitis B Case Studies
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Hepatitis B Case Studies Nina Kim, MD MSc Associate Professor of Medicine University of Washington Harborview Madison Clinic and Hepatitis & Liver Clinic No
More informationOptimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy. Watcharasak Chotiyaputta
Optimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy Watcharasak Chotiyaputta Progression of Liver Disease Goal of HBV Treatment: prevention the development of cirrhosis
More informationLearning Objective. After completing this educational activity, participants should be able to:
Learning Objective After completing this educational activity, participants should be able to: Use patient characteristics and preferences to select HCV treatment strategies that maximize the potential
More information1. SYNOPSIS. AWB-ML21645 Date: April 20, 2016 Title of the observational study
1. SYNOPSIS AWB-ML21645 Date: April 20, 2016 Title of the observational study INVESTIGATORS SPONSOR Noninterventional study on the quality assurance of the therapy of chronic hepatitis C with Peg-(40kd)-Interferon
More informationBritish HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2
British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2 Systematic literature search 2.1 Questions and PICO criteria Data bases: Medline,
More informationTreatment of Chronic Hepatitis C in Non-Responders
Management of Patients with Viral Hepatitis, Paris, 2004 Treatment of Chronic Hepatitis C in Non-Responders Jay H. Hoofnagle INTRODUCTION The treatment of chronic hepatitis C has evolved markedly over
More informationChronic Hepatitis B - Antiviral Resistance in Korea -
Chronic Hepatitis B - Antiviral Resistance in Korea - Young-Suk Lim University of Ulsan College of Medicine Asan Medical Center Seoul, Korea HBV Genome partially double-stranded DNA genome about 3200 nucleotides
More informationCaution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy
Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy Anjana A. Pillai, Emory University Frank A Anania, Emory University Brian L. Pearlman, Emory University
More informationComorbid medical and psychiatric conditions and substance abuse in HCV infected persons on dialysis *
Journal of Hepatology 44 (2006) 864 868 www.elsevier.com/locate/jhep Comorbid medical and psychiatric conditions and substance abuse in persons on dialysis * Adeel A. Butt 1,2,3, *,, Robert Evans 1, Melissa
More information